US Stock Insider Trading | Silvergate disclosed one insider transaction on February 23

K-LinePoet · 2026-02-24T23:59:47+00:00

Yinxiute Company recently disclosed internal personnel trading activities, including Director McEvoy Ashley purchasing 4,300 shares on February 20, 2026. Meanwhile, several executives conducted stock sell transactions on February 12. Insulet Corporation focuses on developing and selling insulin delivery systems, dedicated to providing innovative solutions for diabetes patients.

K-LinePoet

2026-02-24 23:59:47

Abstract generation in progress

On February 23, 2026, PODD disclosed one insider transaction. Director McEvoy Ashley purchased 4,300 shares on February 20, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	McEvoy Ashley	February 20, 2026	Buy	4,300	239.35	$1,029,200
February 17, 2026	Executive	Budden Lauren	February 12, 2026	Sell	622	240.82	$14,980
February 17, 2026	Executive	Singh Prem	February 12, 2026	Sell	861	240.82	$20,730
February 17, 2026	Executive	Kapples John W.	February 12, 2026	Sell	1,929	240.82	$464,500
February 17, 2026	Executive	Cousin Laetitia	February 12, 2026	Sell	564	240.82	$135,800
February 17, 2026	Executive	Benjamin Eric	February 12, 2026	Sell	2,887	240.82	$695,200
January 6, 2026	Executive	Cousin Laetitia	January 2, 2026	Sell	140	282.92	$39,600
January 6, 2026	Director	Huffines Robert Luther	December 31, 2025	Buy	50	284.24	$14,400
December 16, 2025	Director	Frederick Wayne A.I.	December 15, 2025	Sell	1,851	293.09	$542,500
December 8, 2025	Director	STONESIFER TIMOTHY C.	December 5, 2025	Buy	962	311.73	$299,900

[Company Information]

Insulet Corporation, founded in 2000 in Delaware, primarily develops, manufactures, and sells its proprietary insulin delivery systems for insulin-dependent diabetics. The Omnipod platform includes: Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, Omnipod Insulin Management System, and the latest innovation, Omnipod G™. In 2023, it received approval from the U.S. Food and Drug Administration. The company also supplies Pods to Amgen for the Neulasta Onpro kit, a delivery system for Neulasta that helps reduce infection risk after intensive chemotherapy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.